No Data
Argus Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,020
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,115